Novo Nordisk A/S - Share repurchase programme Bagsværd, Denmark, 14 April 2014 - On 30 January 2014, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 15.0 billion to be executed during a 12-month period beginning 30 January

2014.
Under the programme initiated 30 January 2014, Novo Nordisk will repurchase B shares for an amount up to DKK 3.6 billion in the period from 30 January 2014 to 29 April 2014.
Since the announcement as of 7 April 2014, the following transactions have been made under the programme:

Number of B shares Average purchase price Transaction value, DKK Accumulated, last announcement 11,319,000 2,736,072,882

7 April 2014 265,000 239.57 63,486,209

8 April 2014 285,000 235.52 67,123,457

9 April 2014 246,000 238.36 58,635,502

10 April 2014 285,000 238.49 67,970,391

11 April 2014 250,000 230.62 57,656,075


Accumulated under the programme 12,650,000 3,050,944,515

Transactions related to Novo Nordisk's incentive programmes have resulted in a net sale
by Novo Nordisk of 12,000 B shares in the period from 7 April 2014 to 11 April 2014. The shares in these transactions were not part of the Safe Harbour repurchase programme.

Novo Nordisk A/S

Investor Relations

Novo Allé

2880 Bagsværd

Denmark

Telephone:

+45 4444 8888

Internet:

www.novonordisk.com

CVR no:

24 25 67 90

Company announcement No24 / 2014

Page 2 of 2

With the transactions stated above, Novo Nordisk owns a total of 116,450,901 B shares of DKK 0.20, corresponding to 4.2% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,750,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15.0 billion during a 12-month period beginning 30 January 2014. As of 11 April 2014, Novo Nordisk has repurchased a total of 13,142,995 B shares equal to a transaction value of DKK
3,155,750,322.

Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 38,000 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk's B

shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock

Exchange (NVO). For more information, visit novonordisk.com.

Further information

Media:

Anne Margrethe Hauge

Ken Inchausti (US)

+45 4442 3450

+1 609 514 8316

amhg@novonordisk.com kiau@novonordisk.com

Investors:

Kasper Roseeuw Poulsen

+45 3079 4303

krop@novonordisk.com

Frank Daniel Mersebach Lars Borup Jacobsen Daniel Bohsen

Jannick Lindegaard (US)

+45 3079 0604

+45 3075 3479

+45 3079 6376

+1 609 235 8567

fdni@novonordisk.com lbpj@novonordisk.com dabo@novonordisk.com jlis@novonordisk.com

Novo Nordisk A/S

Investor Relations

Novo Allé

2880 Bagsværd

Denmark

Telephone:

+45 4444 8888

Internet:

www.novonordisk.com

CVR no:

24 25 67 90

Company announcement No 24 / 2014

distributed by